Wen Wee Ma, MBBS, associate professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses interrupting the FGFR signaling pathway in pancreatic cancer.
- The recent MPACT trial represents a major milestone in improving the survival of patients with stage IV pancreatic cancer
- The microenvironment (consisting of white blood cells, macrophages, collagens, connective tissues, and fibroblasts) in pancreatic cancer plays a major role in treatment resistance
- The fibroblast growth factor receptor (FGFR) signaling pathway is active in cancer cells in promoting proliferation, growth, and blood vessel formation
- Interrupting this pathway can cause cancer cells to undergo apoptosis
- A clinical trial is underway looking at dovitinib and gemcitabine-based chemotherapy for patients with advanced or metastatic pancreatic cancer